Pulmonary arterial hypertension market to
generate sales of approximately $4.75 billion
by the end of 2024
The Pulmonary Arterial Hypertension (PAH) therapeutics market will experience modest growth from
$3.45 billion in 2014 to $4.75 billion by 2024, representing a Compound Annual Growth Rate (CAGR) of
3.2%.This report on the global pulmonary arterial hypertension (PAH) market offers an insightful and indepth assessment of the current and future market potential of PAH drugs.
The report,” Pulmonary arterial hypertension market” provides analysis of the Pulmonary Arterial
Hypertension (PAH) therapeutics space across the 7MM, including annualized market data from 2014
and forecast to 2024. It discusses market characterization, unmet needs, clinical trial mapping and
implications for the PAH treatment arena.
Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Pulmonary
Arterial Hypertension - Opportunity Analysis and Forecast Report at http://www.absolutereports.com/opportunityanalyzer-pulmonary-arterial-hypertension-opportunityanalysis-and-forecast-to-2024-10120403
The latest report on Pulmonary arterial hypertension market states that the increase in PAH treatment
sales, which will occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK,
and Japan, will be driven by new drug launches, the increased use of double and triple combination
therapies, and patient assistance programs by manufacturers.
Ask for Discount on Pulmonary Arterial Hypertension - Opportunity Analysis and Forecast
Report at – http://www.absolutereports.com/enquiry/request-discount/10120403
The study on the global PAH market also suggests a list of recommendations for new companies aspiring
to enter the market and existing companies willing to accentuate revenue shares. The report concludes
with the profiles of major players in the global PAH market such as Actelion Pharmaceuticals, Ltd., Bayer
HealthCare, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and United
Therapeutics Corporation. Each company profile in the report provides information under the heads:
company overview, financial overview, product portfolio, business strategies, and recent developments.
Request sample PDF of this report at - http://www.absolutereports.com/enquiry/requestsample/10120403
+1 408 520 9750
www.absolutereports.com
Key Findings of this Report:
- The major drivers for growth across the 7MM in the PAH market during the forecast period will be the
launch of the first-in-class prostacyclin receptor agonist, Uptravi marketed by Actelion and the increased
use of combination therapy.
- Low disease awareness, declining population in the 5EU and Japan, high cost of drugs and patent
expirations of branded drugs are the major barriers for growth in the PAH market during the forecast
period.
About Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and
taking visionary decisions based on facts and figures derived from in depth market research. We are one
of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of
data parameters.
Contact–
Mr. Ameya Pingaley
Absolute Reports
+1-408 520 9750
Email – [email protected]
Website: www.absolutereports.com
+1 408 520 9750
www.absolutereports.com